Search Results

Your search filters:

MEDO.AI

Showing 1-1 of about 1 articles.

MEDO.AI

MEDO.ai receives FDA approval to automatically detect hip dysplasia, preventing the leading cause of early hip osteoarthritis and hip replacement surgery

EDMONTON, Alberta, June 16, 2020 (GLOBE NEWSWIRE) -- MEDO.ai, an artificial intelligence technology start-up company dual headquartered in Edmonton, Canada, and Singapore, is pleased to...

June 16, 2020

Showing 1-1 of about 1 articles.

Search Results

MEDO.ai receives FDA approval to automatically detect hip dysplasia, preventing the leading cause of early hip osteoarthritis and hip replacement surgery

Newswire Distribution Network & Management

About Us